CDK7 is considered as an attractive target for treating human cancer, as it controls the activity of key enzymes involved in cell cycle progression, including other cyclin-dependent kinases such as CDK1, CDK2, CDK4, and CDK6. The gene discussed is CDK2; the disease is cancer.